Author is long GNPX, a tiny pre-clinical/early clinical gene therapy biotech, betting on immense upside if early trials succeed.
GNPX — LONG Author is long Genprex, a small Austin-based pre-clinical/early clinical gene therapy company developing cancer and diabetes treatments via licensing deals with MD Anderson and other institutions. The mechanism is that Genprex coordinates clinical trials, FDA relations and patents around scientists' work, and promising animal results are now transitioning to human trials. With a tiny ~$7M market cap and ~2.2M share float, even modest phase 1/phase 2 success could re-rate the company into the hundreds of millions. The author explicitly acknowledges the low probability of success as the main risk.
Even if chances of that happening are somewhat low, if only they do have some initial phase 1 and phase 2 success, we could be looking at a market cap in the 100s of millions. The potential upside is immense.
This Reddit post, published January 16, 2026, features u/realHarryGelb discussing GNPX. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/realHarryGelb · Tickers: GNPX